BioBiz Buzz
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
Podcasting since 2025 • 19 episodes
BioBiz Buzz
Latest Episodes
19. From Genesis to Revelations: Winners & Losers in Pharma’s Most Volatile Year
2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head ...
•
Season 1
•
Episode 19
•
25:09
18. Putting solid tumours under the T-knife: how a next-gen TCR aims to crack them
Engineered T-cell receptor (TCR) therapies promise to do for solid tumours what chimeric antigen receptor T-cell (CAR-T) therapies have done for haematological malignancies.The two approaches are conceptually similar – each involves the ...
•
Season 1
•
Episode 18
•
22:44
17. Democratizing Drug Discovery: How Lilly ExploR&D Is Changing the Biotech Playbook
The traditional biotech funding model hasn't fundamentally changed in decades: brilliant founders with promising science face an impossible choice; build expensive internal R&D capabilities or negotiate partnerships on terms controlled by B...
•
Season 1
•
Episode 17
•
27:46
16. The Smart Money Talks: Inside Sofinnova's Bold €650M Fundraise
In a fundraising environment marked by cautious institutional investors, tightening belts, and widespread scepticism about early-stage venture capital, Sofinnova Partners has just closed its flagship Capital XI fund at €650 million, significant...
•
Season 1
•
Episode 16
•
25:02
15. Targeting Misfolded SOD1 in ALS: A First-in-Class Antibody Shows Promise
This episode of BioBiz Buzz explores AL-S Pharma's pioneering approach to treating amyotrophic lateral sclerosis through AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1 protein. Host Mike Ward speaks with Dr. Michael Salzm...
•
Season 1
•
Episode 15
•
31:47
